Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Менопауза как фактор риска кардиометаболических расстройств
Менопауза как фактор риска кардиометаболических расстройств
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Согласно статистическим данным Всемирной организации здравоохранения, 57% в структуре общей смертности в России занимают сердечно-сосудистые заболевания (ССЗ). И эта цифра постоянно увеличивается: еще 10–15 лет назад она не превышала 41,1%. В период климактерия развитие ССЗ ускоряет эстрогенный дефицит, вызывающий типичные менопаузальные симптомы – приливы, ночную потливость и другие вазомоторные нарушения. Практикующему акушеру-гинекологу важно не пропустить даже самые ранние климактерические симптомы и своевременно начать менопаузальную терапию.
Полный текст
Список литературы
1. Freedman RR. Menopausal hot flashes: mechanisms, endocrinology, treatment. J Steroid Biochem Mol Biol 2014; 142: 115–20.
2. Archer DF, Sturdee DW, Baber R, et al. Menopausal hot flushes and night sweats: where are we now? Climacteric 2011; 14: 515–28.
3. Avis NE, Crawford SL, Greendale G et al; the Study of Women’s Health Across the Nation (SWAN). Duration of menopausal vasomotor symptoms over the menopause transition [published online ahead of print February 16, 2015]. JAMA Intern Med. doi:10.1001/jamainternmed. 2014.8063
4. Crandall CJ, Aragaki A, Cauley JA et al. Associations of menopausal vasomotor symptoms with fracture incidence. J Clin Endocrinol Metab 2015; 100: 524–34.
5. Tepper PG, Brooks MM, Randolph JF Jr et al. Characterizing the trajectories of vasomotor symptoms across the menopausal transition. Menopause 2016; 23: 1067–74.
6. Thurston RC, Chang Y, Barinas-Mitchell E et al. Physiologically assessed hot flashes and endothelial function among midlife women. Menopause 2017; 24: 886–93.
7. Thurston RC, Sutton-Tyrell K, Everson-Rose SA et al. Hot flashes and subclinical cardiovascular disease. Findings from the Study of Women’s Health Across the Nation Heart Study. Circulation 2008; 118: 1234–40.
8. Allison MA, Manson JE, Aragaki A, et al. Vasomotor symptoms and coronary artery calcium in postmenopausal women. Menopause 2010; 17: 1136–45.
9. Svartberg J, von Muhlen D, Kritz-Silverstein D, Barrett-Connor E. Vasomotor symptoms and mortality: the Rancho Bernardo Study. Menopause 2009; 16: 888–91.
10. Muka T, Oliver-Williams C, Colpani V et al. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: a systematic review and meta-analysis. PLoS One 2016; 11: e0157417.
11. Thurston RC, Johnson BD, Shufelt CL et al. Menopausal symptoms and cardiovascular disease mortality in the Women’s Ischemia Syndrome Evaluation (WISE). Menopause 2017; 24: 126–32.
12. Rizzo MR, Leo S, De Franciscis P et al. Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome. Age (Dordr) 2014; 36 (1): 265–74.
13. Sutton-Tyrrell K, Wildman R, Matthews K et al. Sex hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women en rolled in the Study of Women Across the Nation (SWAN). Circulation 2005; 111: 1242–9.
14. Janssen I, Powel LH, Kazlauskaite R et al. Testosterone and Visceral Fat in Midlife Women: The Study of Women’s Health Across the Nation (SWAN) Fat Patterning Study. Obesity 2010; 18 (3): 604–10.
15. Sutton-Tyrrell K, Wildman R, Matthews K
et al. Sex hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 2005; 111: 1242–9.
16. Byrd JB, Brook RD. A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension. J Hum Hypertens 2014; 28: 3–9.
17. Engeli S, Bohnke J, Gorzelniak K et al. Weight loss and the renin-angiotensinaldosterone system. Hypertension 2005; 45: 356–62.
18. Gray KE, Katon JG, LeBlanc ES et al. Vasomotor symptom characteristics: are they risk factors for incident diabetes? Menopause 2018; 25 (5): 520–30.
19. Sturdee DW, Hunter MS, Maki PM et al. The menopausal hot flush: a review. Climacteric 2017; 20 (4): 296–305.
20. Клинические рекомендации (протоколы лечения). Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. M., 2014.
21. Caprio M, Antelmi A, Chetrite G et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 2011; 152 (1): 113–25.
22. International Consultation on Sexual Medicine Organized under the auspices of the International Consultation on Urological Diseases (ICUD) and the International Society for Sexual Medicine (ISSM) July 10–13, 2009. ICSM2009_finalprogram_website.pdf
23. Dinger J, Bardenheuer K, Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric 2016; 19 (4): 349–56.
24. De Villiers TJ, Pines A, Panay N et al. On behalf of the International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013, 16: 316–37.
25. Журавель А.С. Влияние менопаузальной гормональной и альтернативной терапии на жесткость сосудистой стенки. Автореф. ... дис. канд. мед. наук.
2. Archer DF, Sturdee DW, Baber R, et al. Menopausal hot flushes and night sweats: where are we now? Climacteric 2011; 14: 515–28.
3. Avis NE, Crawford SL, Greendale G et al; the Study of Women’s Health Across the Nation (SWAN). Duration of menopausal vasomotor symptoms over the menopause transition [published online ahead of print February 16, 2015]. JAMA Intern Med. doi:10.1001/jamainternmed. 2014.8063
4. Crandall CJ, Aragaki A, Cauley JA et al. Associations of menopausal vasomotor symptoms with fracture incidence. J Clin Endocrinol Metab 2015; 100: 524–34.
5. Tepper PG, Brooks MM, Randolph JF Jr et al. Characterizing the trajectories of vasomotor symptoms across the menopausal transition. Menopause 2016; 23: 1067–74.
6. Thurston RC, Chang Y, Barinas-Mitchell E et al. Physiologically assessed hot flashes and endothelial function among midlife women. Menopause 2017; 24: 886–93.
7. Thurston RC, Sutton-Tyrell K, Everson-Rose SA et al. Hot flashes and subclinical cardiovascular disease. Findings from the Study of Women’s Health Across the Nation Heart Study. Circulation 2008; 118: 1234–40.
8. Allison MA, Manson JE, Aragaki A, et al. Vasomotor symptoms and coronary artery calcium in postmenopausal women. Menopause 2010; 17: 1136–45.
9. Svartberg J, von Muhlen D, Kritz-Silverstein D, Barrett-Connor E. Vasomotor symptoms and mortality: the Rancho Bernardo Study. Menopause 2009; 16: 888–91.
10. Muka T, Oliver-Williams C, Colpani V et al. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: a systematic review and meta-analysis. PLoS One 2016; 11: e0157417.
11. Thurston RC, Johnson BD, Shufelt CL et al. Menopausal symptoms and cardiovascular disease mortality in the Women’s Ischemia Syndrome Evaluation (WISE). Menopause 2017; 24: 126–32.
12. Rizzo MR, Leo S, De Franciscis P et al. Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome. Age (Dordr) 2014; 36 (1): 265–74.
13. Sutton-Tyrrell K, Wildman R, Matthews K et al. Sex hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women en rolled in the Study of Women Across the Nation (SWAN). Circulation 2005; 111: 1242–9.
14. Janssen I, Powel LH, Kazlauskaite R et al. Testosterone and Visceral Fat in Midlife Women: The Study of Women’s Health Across the Nation (SWAN) Fat Patterning Study. Obesity 2010; 18 (3): 604–10.
15. Sutton-Tyrrell K, Wildman R, Matthews K
et al. Sex hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 2005; 111: 1242–9.
16. Byrd JB, Brook RD. A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension. J Hum Hypertens 2014; 28: 3–9.
17. Engeli S, Bohnke J, Gorzelniak K et al. Weight loss and the renin-angiotensinaldosterone system. Hypertension 2005; 45: 356–62.
18. Gray KE, Katon JG, LeBlanc ES et al. Vasomotor symptom characteristics: are they risk factors for incident diabetes? Menopause 2018; 25 (5): 520–30.
19. Sturdee DW, Hunter MS, Maki PM et al. The menopausal hot flush: a review. Climacteric 2017; 20 (4): 296–305.
20. Клинические рекомендации (протоколы лечения). Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. M., 2014.
21. Caprio M, Antelmi A, Chetrite G et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 2011; 152 (1): 113–25.
22. International Consultation on Sexual Medicine Organized under the auspices of the International Consultation on Urological Diseases (ICUD) and the International Society for Sexual Medicine (ISSM) July 10–13, 2009. ICSM2009_finalprogram_website.pdf
23. Dinger J, Bardenheuer K, Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric 2016; 19 (4): 349–56.
24. De Villiers TJ, Pines A, Panay N et al. On behalf of the International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013, 16: 316–37.
25. Журавель А.С. Влияние менопаузальной гормональной и альтернативной терапии на жесткость сосудистой стенки. Автореф. ... дис. канд. мед. наук.
Авторы
Вера Ефимовна Балан
Доктор медицинских наук, профессор, гинеколог-эндокринолог,
врач высшей категории, руководитель поликлинического отделения МОНИИАГ, президент Российской ассоциации по менопаузе.
Доктор медицинских наук, профессор, гинеколог-эндокринолог,
врач высшей категории, руководитель поликлинического отделения МОНИИАГ, президент Российской ассоциации по менопаузе.
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.